HONG KONG - Immuno-oncology company Ziopharm Oncology Inc. and cell therapy company Triarm Therapeutics Ltd. are set to establish a joint venture (JV), Eden Biocell Ltd., to develop and commercialize CAR T therapies targeting CD19 antigen in the greater China region and South Korea, with the use of a technology platform named Sleeping Beauty.
HONG KONG – China bioprocessing technology firm Hangzhou Just Biotherapeutics Ltd. (HJB) and clinical-stage biotech Mabspace Biosciences Co. Ltd. have entered a merger agreement to establish a biotherapeutics maker, Transcenta Holding Ltd., with the aim of shortening the time from target to biologics license applications, and setting up a next-generation GMP facility that supports the development and commercialization of molecules both in-house and from its partners.
HONG KONG - Immuno-oncology company Ziopharm Oncology Inc. and cell therapy company Triarm Therapeutics Ltd. are set to establish a joint venture (JV), Eden Biocell Ltd., to develop and commercialize CAR T therapies targeting CD19 antigen in the greater China region and South Korea, with the use of a technology platform named Sleeping Beauty.
HONG KONG – Chugai Pharmaceutical Co. Ltd., a Japanese subsidiary of Roche Holding AG, won approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Foundationone CDx, Foundation Medicine Inc.'s genomic profiling test for solid tumors and companion diagnostics for molecularly targeted drugs.
HONG KONG – Five years into the partnership with Eli Lilly and Co., an amendment in late December to their license agreement lets Hutchison China Meditech Ltd. (Chi-Med) take a larger role in the development and commercialization of fruquintinib in China.
HONG KONG – With an NDA for tislelizumab currently under review at the National Medical Products Agency (NMPA) for relapsed or refractory classical Hodgkin lymphoma, China biotech Beigene Ltd. started enrolling patients into two global phase III trials testing the PD-1-inhibiting antibody in gastric cancer and esophageal squamous cell carcinoma (ESCC).
HONG KONG – Five years into the partnership with Eli Lilly and Co., an amendment in late December to their license agreement lets Hutchison China Meditech Ltd. (Chi-Med) take a larger role in the development and commercialization of fruquintinib in China.
HONG KONG – With an NDA for tislelizumab currently under review at the National Medical Products Agency (NMPA) for relapsed or refractory classical Hodgkin lymphoma, China biotech Beigene Ltd. started enrolling patients into two global phase III trials testing the PD-1-inhibiting antibody in gastric cancer and esophageal squamous cell carcinoma (ESCC).
